Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 8/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | METAP2 | P50579 | 2/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | PLK4 | O00444 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | LTK | P29376 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31104474 | 1.00 | NOS1 (0.55) | NOS1MAPTDYRK1AMETAP2CSNK2A1 | |
| SCHEMBL25395813 | 0.80 | NOS1 (0.50) | NOS1MAPTDYRK1AMETAP2FGFR1 | |
| SCHEMBL29410379 | 0.76 | NOS1 (0.55) | NOS1MAPTDYRK1AMETAP2CSNK2A1 | |
| SCHEMBL15687064 | 0.76 | NOS1 (0.55) | NOS1MAPTDYRK1AMETAP2CSNK2A1 | |
| SCHEMBL15288493 | 0.76 | NOS1 (0.55) | NOS1MAPTDYRK1AMETAP2CSNK2A1 | |
| SCHEMBL2269592 | 0.76 | NOS1 (0.50) | NOS1MAPTDYRK1AFGFR1KDM4E | |
| SCHEMBL23083828 | 0.76 | MAPT (0.61) | NOS1MAPTDYRK1AFGFR1KDM4E | |
| SCHEMBL1072434 | 0.76 | MAPT (0.52) | NOS1MAPTDYRK1AFGFR1KDM4E | |
| SCHEMBL23070918 | 0.74 | NOS1 (0.48) | NOS1MAPTDYRK1AMETAP2CSNK2A1 | |
| SCHEMBL24344349 | 0.72 | NOS1 (0.50) | NOS1MAPTDYRK1AMETAP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739390-A1 | 2-(1H-INDOL-4-YL)METHYL)2H-INDAZOLE DERIVATIVES AS FACTOR B INHIBITORS | Sitala Bio Ltd (GB) | 2026-05-13 | — | — | EP | disclosed |
| US-12565476-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-04-10 | — | — | US | disclosed |
| WO-2025052129-A1 | PYRIDINE DERIVATIVES WHICH ACT AS INHIBITORS OF MPTP. | NRG THERAPEUTICS LTD (GB) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025049994-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20250059161-A1 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | VIVIDION THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| WO-2025008451-A1 | 2-(1H-INDOL-4-YL)METHYL)2H-INDAZOLE DERIVATIVES AS FACTOR B INHIBITORS | SITALA BIO LTD (GB) | 2025-01-09 | — | — | WO | disclosed |
| CN-113795483-B | Carboxamide-pyrimidine derivatives as SHP2 antagonists | 默克专利有限公司 | 2024-12-31 | — | — | CN | disclosed |
| WO-2024182693-A1 | 2-AZASPIRO[3.3]HEPTANE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER | VIVIDION THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| WO-2024175081-A1 | SHP2 INHIBITOR COMPOUND AND USE THEREOF | 深圳真实生物医药科技有限公司 | 2024-08-29 | — | — | WO | disclosed |
| US-20210101870-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-04-08 | — | — | US | disclosed |
| US-20210070739-A1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-10882848-B2 | 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds | HOFFMANN-LA ROCHE, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200281926-A1 | CARBOXAMIDE-PYRIMIDINE DERIVATIVES AS SHP2 ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-09-10 | — | — | US | disclosed |
| US-10590090-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
| EP-3558967-A1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | H. Hoffnabb-La Roche Ag (CH) | 2019-10-30 | — | — | EP | disclosed |
| US-20190308955-A1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2019-10-10 | — | — | US | disclosed |
| US-20190210977-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2019-07-11 | — | — | US | disclosed |
| WO-2018115218-A1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018013597-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590090-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN22, PTPN2 | NOS1 1290/4885MAPT 3793/4885DYRK1A 754/4885 |
| US-20190210977-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN2, PTPN22 | NOS1 3875/4885MAPT 3462/4885DYRK1A 578/4885 |
| US-20250059161-A1 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | STAT3, JAK2, STAT1 | NOS1 2239/4885MAPT 4261/4885DYRK1A 2843/4885 |
| US-10882848-B2 | 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds | EGFR, ERBB2, ERBB3 | NOS1 4864/4885MAPT 2074/4885DYRK1A 430/4885 |
| US-20210070739-A1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | EGFR, ERBB2, ERBB3 | NOS1 4864/4885MAPT 2074/4885DYRK1A 430/4885 |
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | EP300, CREBBP, HDAC1 | NOS1 4640/4885MAPT 1252/4885DYRK1A 4137/4885 |
| US-20210101870-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN22, PTPN2 | NOS1 1290/4885MAPT 3793/4885DYRK1A 754/4885 |
| US-20190308955-A1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | EGFR, ERBB2, ERBB3 | NOS1 4864/4885MAPT 2074/4885DYRK1A 430/4885 |
| US-12565476-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN6, PTPN2 | NOS1 3789/4885MAPT 2897/4885DYRK1A 757/4885 |
| US-20200281926-A1 | CARBOXAMIDE-PYRIMIDINE DERIVATIVES AS SHP2 ANTAGONISTS | PTPN5, PTPN2, PTPN1 | NOS1 3629/4885MAPT 4596/4885DYRK1A 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.